SOUTH SAN FRANCISCO, Calif. & SEOUL, South Korea--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Ildong Pharmaceutical, today announced an agreement under which Ildong will license a suite of Twist VHH antibody libraries to use to discover and develop antibodies for applications in immuno-oncology.
A Phase 1 study on new drug candidate IDG16177 of novel oral treatment for type 2 diabetes, which is being developed by Ildong Pharmaceutical, is initiated in Germany.
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into a strategic collaboration with Ildong Pharmaceutical Co., Ltd. (“Ildong”), a leading pharmaceutical company in South Korea, to accelerate the development of several of Ildong’s proprietary projects through access to Evotec’s INDiGO platform.
Medifron DBT, Dong-A ST, Medipost, Boryung Pharmaceutical, Ildong Pharmaceutical, Daewoong Pharmaceutical, SK Chemicals, and SK Biopharmaceuticals are working on treatments in neurology disorders such as Alzheimer’s disease.
Controversy Reignites over Hostile M&A of ildong Pharmaceuticals by Green Cross